Molecular Endocrinology, Vol 10, 1214-1226, Copyright © 1996 by Endocrine Society

ARTICLES

Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor

S Roux, B Terouanne, P Balaguer, N Jausons-Loffreda, M Pons, P Chambon, H Gronemeyer and JC Nicolas
INSERM U439, Montpellier, France.

Mutation of isoleucine 747 to threonine in the C-terminal part of the ligand-binding domain (LBD) of the human glucocorticoid receptor (GR) alters the ligand specificity for transactivation. Natural glucocorticoids such as cortisol or corticosterone were completely inactive with the mutant 1747T, whereas synthetic steroids like dexamethasone efficiently stimulated GR 1747T-mediated transactivation. However, the corresponding ligand dose-response curve for dexamethasone- induced transactivation was shifted to higher concentrations when compared with that obtained with the wild type GR. Neither this shift nor the inability of cortisol to activate the 1747T mutant was due to an altered in vitro ligand-binding affinity. In the canonical three- dimensional structure of nuclear receptor LBDs, isoleucine 747 is in the direct vicinity of residues that contribute to the ligand-binding pocket. Moreover, it is located in the C-terminal LBD region, which harbors the conserved core of the activation function AF-2 and undergoes a ligand-induce transconformation, required to generate the surface interacting with putative transcriptional intermediary factors/coactivators of AF-2. The phenotype of 1747T mutant is discussed in view of the possible consequences of the mutation on the various events which, according to the model, lead to a transcriptionally competent AF-2.

This article has been cited by other articles:

				P. Carlsson, K. F. Koehler, and L. Nilsson Glucocorticoid Receptor Point Mutation V571M Facilitates Coactivator and Ligand Binding by Structural Rearrangement and Stabilization Mol. Endocrinol., August 1, 2005; 19(8): 1960 - 1977. [Abstract] [Full Text] [PDF]

				M. B. Kumar, D. W. Potter, R. E. Hormann, A. Edwards, C. M. Tice, H. C. Smith, M. A. Dipietro, M. Polley, M. Lawless, P. R. N. Wolohan, et al. Highly Flexible Ligand Binding Pocket of Ecdysone Receptor: A SINGLE AMINO ACID CHANGE LEADS TO DISCRIMINATION BETWEEN TWO GROUPS OF NONSTEROIDAL ECDYSONE AGONISTS J. Biol. Chem., June 25, 2004; 279(26): 27211 - 27218. [Abstract] [Full Text] [PDF]

				C. Teyssier, K. Belguise, F. Galtier, V. Cavailles, and D. Chalbos Receptor-Interacting Protein 140 Binds c-Jun and Inhibits Estradiol-Induced Activator Protein-1 Activity by Reversing Glucocorticoid Receptor-Interacting Protein 1 Effect Mol. Endocrinol., February 1, 2003; 17(2): 287 - 299. [Abstract] [Full Text] [PDF]

				N. Poujol, S. Lumbroso, B. Terouanne, J.-M. A. Lobaccaro, W. Bourguet, and C. Sultan Pathophysiology of Androgen Insensitivity Syndromes: Molecular and Structural Approaches of Natural and Engineered Androgen Receptor Mutations at Amino Acid 743 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5793 - 5800. [Abstract] [Full Text] [PDF]

				E. Demirpence, A. Semlali, J. Oliva, P. Balaguer, E. Badia, M.-J. Duchesne, J.-C. Nicolas, and M. Pons An Estrogen-responsive Element-targeted Histone Deacetylase Enzyme Has an Antiestrogen Activity That Differs from That of Hydroxytamoxifen Cancer Res., November 15, 2002; 62(22): 6519 - 6528. [Abstract] [Full Text] [PDF]

				N. Yoshikawa, Y. Makino, K. Okamoto, C. Morimoto, I. Makino, and H. Tanaka Distinct Interaction of Cortivazol with the Ligand Binding Domain Confers Glucocorticoid Receptor Specificity. CORTIVAZOL IS A SPECIFIC LIGAND FOR THE GLUCOCORTICOID RECEPTOR J. Biol. Chem., February 8, 2002; 277(7): 5529 - 5540. [Abstract] [Full Text] [PDF]

				S. Roux, B. Terouanne, B. Couette, M.-E. Rafestin-Oblin, and J.-C. Nicolas Conformational Change in the Human Glucocorticoid Receptor Induced by Ligand Binding Is Altered by Mutation of Isoleucine 747 by a Threonine J. Biol. Chem., April 9, 1999; 274(15): 10059 - 10065. [Abstract] [Full Text] [PDF]

				A. Philips, C. Teyssier, F. Galtier, C. Rivier-Covas, J.-M. Rey, H. Rochefort, and D. Chalbos FRA-1 Expression Level Modulates Regulation of Activator Protein-1 Activity by Estradiol in Breast Cancer Cells Mol. Endocrinol., July 1, 1998; 12(7): 973 - 985. [Abstract] [Full Text]

				C. Teyssier, K. Belguise, F. Galtier, and D. Chalbos Characterization of the Physical Interaction between Estrogen Receptor alpha and JUN Proteins J. Biol. Chem., September 21, 2001; 276(39): 36361 - 36369. [Abstract] [Full Text] [PDF]